APA (7th ed.) Citation

S, S., BE, S., S, D., Jr, L. E., AL, J., DH, K., . . . JF, C. (2026). Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial. Advances in therapy, 43(6), 2510. https://doi.org/10.1007/s12325-026-03533-3

Chicago Style (17th ed.) Citation

S, Schreiber, Sands BE, Danese S, Loftus EV Jr, Jeong AL, Kim DH, Lee YN, and Colombel JF. "Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial." Advances in Therapy 43, no. 6 (2026): 2510. https://doi.org/10.1007/s12325-026-03533-3.

MLA (9th ed.) Citation

S, Schreiber, et al. "Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial." Advances in Therapy, vol. 43, no. 6, 2026, p. 2510, https://doi.org/10.1007/s12325-026-03533-3.